• Arch Biopartners (ARCH) has hired Farris Smith as a Strategic Advisor
  • Farris Smith started his career with AP Moller in 2001 and joined Novo Nordisk in 2003 as head of Finance and Human Resources for the Arabian Gulf countries
  • He has since held finance and operations positions of growing size and complexity throughout the global Novo Nordisk organization
  • Arch Biopartners is a clinical-stage company focused on the development of innovative technologies
  • Arch Biopartners (ARCH) is down 0.34 per cent, trading at C$2.96 at 10:21 am EST

Arch Biopartners (ARCH) welcomes Farris Smith of Novo Nordisk Canada as a Strategic Advisor.

Farris Smith started his career with AP Moller in 2001 and joined Novo Nordisk in 2003 as head of Finance and Human Resources for the Arabian Gulf countries.

He has since held finance and operations positions of growing size and complexity throughout the global Novo Nordisk organization.

From 2010 to 2012, he led the Finance and Business Development organization for Region Latin America and, in 2013, moved to France as CFO for France and BeLux.

In 2016, he transitioned to his current role as CFO for Novo Nordisk’s Canadian business and supported the organization through a period of significant development.

Farris was recognized as Finance Manager of the year in 2022, an award recognizing excellence in leadership across all of Novo Nordisk.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.

“Arch Biopartners has demonstrated an ability and commitment to bring forward innovative drug candidates,” said Farris Smith.

“We are looking forward to working with Farris to help guide Arch as the company grows in pursuit of drug approval and commercial opportunities,” said Richard Muruve, CEO of Arch Biopartners.

Arch Biopartners is a clinical-stage company focused on the development of innovative technologies.  

Arch Biopartners (ARCH) is down 0.34 per cent, trading at C$2.96 at 10:21 am EST.


More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.